Iopromide | CAS#73334-07-3

MedKoo Cat#: 525289 | Name: Iopromide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iopromide is a low osmolar, non-ionic contrast agent for intravascular use. Iopromide is a molecule used as a contrast medium.

Chemical Structure

Iopromide

CAS#73334-07-3

Theoretical Analysis

MedKoo Cat#: 525289

Name: Iopromide

CAS#: 73334-07-3

Chemical Formula: C18H24I3N3O8

Exact Mass: 790.8697

Molecular Weight: 791.12

Elemental Analysis: C, 27.33; H, 3.06; I, 48.12; N, 5.31; O, 16.18

Price and Availability

Size	Price	Availability
50mg	USD 250.00	2 Weeks
100mg	USD 400.00	2 Weeks
250mg	USD 650.00	2 Weeks
500g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Iopromide; SHL 414C; Ultravist; Ultravist (pharmacy bulk); Ultravist 150; Ultravist 240; Ultravist 300; Ultravist 370; UNII-712BAC33MZ; ZK 35760.

IUPAC/Chemical Name

1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-((methoxyacetyl)amino)-N-methyl-

InChi Key

DGAIEPBNLOQYER-IUCAKERBSA-N

InChi Code

InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)/t8-,9-/m0/s1

SMILES Code

c1(c(c(c(I)c(c1I)NC(COC)=O)C(NC[C@@H](CO)O)=O)I)C(N(C[C@@H](CO)O)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

In vitro activity:

After adding Sal B (10, 50, and 100 μmol/L), the cell viability increased (Figure 1(b)), indicating that Sal B can mitigate HK-2 cell injury caused by iopromide. After treatment with iopromide, some of the nuclei showed high-density fluorescence and apoptotic characteristics, such as karyopyknosis and karyorrhexis. However, these apoptotic nuclei decreased after treatment with different concentrations of Sal B (Figures 1(c) and 1(d)). Iopromide significantly increased the levels of Bax/Bcl-2 and cleaved caspase-3. Reference: Evid Based Complement Alternat Med. 2022 Jun 26;2022:8400496. https://pubmed.ncbi.nlm.nih.gov/35795279/

In vivo activity:

CIN (contrast-induced nephropathy) was induced by the intravenous injection of iodinated contrast medium (CM) iopromide (1.8 g/kg) into Sprague Dawley rats with normal food intake or 40% reduced food intake, 4 weeks prior to iopromide administration. This study found that CR (calorie restriction) was protective of CIN, assessed by renal structure and function. Reference: In Vivo. 2021 Nov-Dec;35(6):3221-3232. https://pubmed.ncbi.nlm.nih.gov/34712381/

	Solvent	mg/mL	mM
Solubility
	DMF	3.0	3.79
	DMSO	100.0	126.40
	PBS (pH 7.2)	3.0	3.79
	Water	100.0	126.40

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 791.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Pei MX, Dong SJ, Gao XY, Luo T, Fan D, Jin JF, Zhao XD, Chen YL. Salvianolic Acid B Attenuates Iopromide-Induced Renal Tubular Epithelial Cell Injury by Inhibiting the TLR4/NF-κB/NLRP3 Signaling Pathway. Evid Based Complement Alternat Med. 2022 Jun 26;2022:8400496. doi: 10.1155/2022/8400496. PMID: 35795279; PMCID: PMC9251145. 2. Tsai YF, Yang JS, Tsai FJ, Cheng YD, Chiu YJ, Tsai SC. High Concentration of Iopromide Induces Apoptosis and Autophagy in Human Embryonic Kidney Cells via Activating a ROS-dependent Cellular Stress Pathway. In Vivo. 2021 Nov-Dec;35(6):3221-3232. doi: 10.21873/invivo.12617. PMID: 34697153; PMCID: PMC8627727.

In vitro protocol:

In vivo protocol:

. Tsai YF, Yang JS, Tsai FJ, Cheng YD, Chiu YJ, Tsai SC. High Concentration of Iopromide Induces Apoptosis and Autophagy in Human Embryonic Kidney Cells via Activating a ROS-dependent Cellular Stress Pathway. In Vivo. 2021 Nov-Dec;35(6):3221-3232. doi: 10.21873/invivo.12617. PMID: 34697153; PMCID: PMC8627727.

1: Achenbach S, Paul JF, Laurent F, Becker HC, Rengo M, Caudron J, Leschka S, Vignaux O, Knobloch G, Benea G, Schlosser T, Andreu J, Cabeza B, Jacquier A, Souto M, Revel D, Qanadli SD, Cademartiri F; X-ACT Study Group. Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial. Eur Radiol. 2016 Jun 7. [Epub ahead of print] PubMed PMID: 27271922. 2: Cruz-Zavala AS, Pat-Espadas AM, Rangel-Mendez JR, Chazaro-Ruiz LF, Ascacio-Valdes JA, Aguilar CN, Cervantes FJ. Immobilization of metal-humic acid complexes in anaerobic granular sludge for their application as solid-phase redox mediators in the biotransformation of iopromide in UASB reactors. Bioresour Technol. 2016 May;207:39-45. doi: 10.1016/j.biortech.2016.01.125. Epub 2016 Feb 8. PubMed PMID: 26868154. 3: Zhu Z, Han H, Zhu J, Zhang J, Du R, Ni J, Ying C, An X, Zhang R. Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis. Biomed Mater Eng. 2015;26(1-2):79-88. doi: 10.3233/BME-151551. PubMed PMID: 26484558; PubMed Central PMCID: PMC4923742. 4: Keen OS, Love NG, Aga DS, Linden KG. Biodegradability of iopromide products after UV/H₂O₂ advanced oxidation. Chemosphere. 2016 Feb;144:989-94. doi: 10.1016/j.chemosphere.2015.09.072. Epub 2015 Oct 2. PubMed PMID: 26433937. 5: Moon BF, Jones KM, Chen LQ, Liu P, Randtke EA, Howison CM, Pagel MD. A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH. Contrast Media Mol Imaging. 2015 Nov-Dec;10(6):446-55. doi: 10.1002/cmmi.1647. Epub 2015 Jun 25. PubMed PMID: 26108564; PubMed Central PMCID: PMC4691225. 6: Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, Chen LB. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015 Oct;31(7):1281-91. doi: 10.1007/s10554-015-0688-9. Epub 2015 Jun 10. PubMed PMID: 26058857. 7: Schmid D, Micić V, Laumann S, Hofmann T. Measuring the reactivity of commercially available zero-valent iron nanoparticles used for environmental remediation with iopromide. J Contam Hydrol. 2015 Oct;181:36-45. doi: 10.1016/j.jconhyd.2015.01.006. Epub 2015 Feb 14. PubMed PMID: 25708601. 8: Singh RR, Lester Y, Linden KG, Love NG, Atilla-Gokcumen GE, Aga DS. Application of metabolite profiling tools and time-of-flight mass spectrometry in the identification of transformation products of iopromide and iopamidol during advanced oxidation. Environ Sci Technol. 2015 Mar 3;49(5):2983-90. doi: 10.1021/es505469h. Epub 2015 Feb 17. PubMed PMID: 25651339. 9: Cho HY, Choi SJ, Lee SW, Kim YW, Lee CK, Lee SW. Iopromide in combination with IFN-γ induces the activation of HMC-1 cells via IL-4 and MCP-1 expression. Cell Immunol. 2015 Feb;293(2):95-103. doi: 10.1016/j.cellimm.2014.12.010. Epub 2015 Jan 5. PubMed PMID: 25585347. 10: Gerk U, Krüger A, Franke RP, Jung F. Effect of radiographic contrast media (Iodixanol, Iopromide) on hemolysis. Clin Hemorheol Microcirc. 2014;58(1):171-4. doi: 10.3233/CH-141879. PubMed PMID: 25227190. 11: Xu BJ, Gao P, Xue G, He MQ, Wu F. [Study on the iopromide-degrading characteristics of strain Pseudomonas sp. I-24 via co-metabolism]. Huan Jing Ke Xue. 2014 Apr;35(4):1443-8. Chinese. PubMed PMID: 24946600. 12: Wang YC, Tang A, Chang D, Zhang SJ, Ju S. Significant perturbation in renal functional magnetic resonance imaging parameters and contrast retention for iodixanol compared with iopromide: an experimental study using blood-oxygen-level-dependent/diffusion-weighted magnetic resonance imaging and computed tomography in rats. Invest Radiol. 2014 Nov;49(11):699-706. doi: 10.1097/RLI.0000000000000073. PubMed PMID: 24879299. 13: Gros M, Cruz-Morato C, Marco-Urrea E, Longrée P, Singer H, Sarrà M, Hollender J, Vicent T, Rodriguez-Mozaz S, Barceló D. Biodegradation of the X-ray contrast agent iopromide and the fluoroquinolone antibiotic ofloxacin by the white rot fungus Trametes versicolor in hospital wastewaters and identification of degradation products. Water Res. 2014 Sep 1;60:228-41. doi: 10.1016/j.watres.2014.04.042. Epub 2014 May 8. PubMed PMID: 24867600. 14: Bavbek S, Sözener ZC, Aydin O, Ozdemir SK, Gül U, Heper AO. First case report of acute generalized exanthematous pustulosis due to intravenous iopromide. J Investig Allergol Clin Immunol. 2014;24(1):66-7. PubMed PMID: 24765887. 15: García M, Aguirre U, Martinez A, Ruiz B, Lertxundi U, Aguirre C. Acute adverse reactions to iopromide vs iomeprol: a retrospective analysis of spontaneous reporting from a radiology department. Br J Radiol. 2014 Jan;87(1033):20130511. doi: 10.1259/bjr.20130511. Epub 2013 Nov 4. PubMed PMID: 24191124; PubMed Central PMCID: PMC4612218. 16: Lütke Eversloh C, Henning N, Schulz M, Ternes TA. Electrochemical treatment of iopromide under conditions of reverse osmosis concentrates--elucidation of the degradation pathway. Water Res. 2014 Jan 1;48:237-46. doi: 10.1016/j.watres.2013.09.035. Epub 2013 Sep 25. PubMed PMID: 24140349. 17: Verburg FA, Apitzsch J, Lensing C, Kuhl CK, Pietsch H, Mottaghy FM, Behrendt FF. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT. Eur J Radiol. 2013 Dec;82(12):2348-52. doi: 10.1016/j.ejrad.2013.09.013. Epub 2013 Sep 21. PubMed PMID: 24113432. 18: Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014 Jul;55(6):707-14. doi: 10.1177/0284185113504753. Epub 2013 Sep 16. PubMed PMID: 24043880. 19: Buszman PP, Tellez A, Afari ME, Peppas A, Conditt GB, Rousselle SD, McGregor JC, Stenoien M, Kaluza GL, Granada JF. Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. JACC Cardiovasc Interv. 2013 Aug;6(8):883-90. doi: 10.1016/j.jcin.2013.04.013. PubMed PMID: 23968706. 20: Buszman PP, Tellez A, Afari M, Cheng Y, Conditt GB, McGregor JC, Milewski K, Stenoien M, Kaluza GL, Granada JF. Stent healing response following delivery of paclitaxel via durable polymeric matrix versus iopromide-based balloon coating in the familial hypercholesterolaemic swine model of coronary injury. EuroIntervention. 2013 Aug 22;9(4):510-6. doi: 10.4244/EIJV9I4A82. PubMed PMID: 23965356.